RxDoctor Payments Data

Brian Leberthon, MD

Hematology & Oncology · West Covina, CANPI 1326023979

Payments from drug & device makers

$508,014in general payments, 2019–2025

Across 1,733 payments — averaging $293.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$464K
  • Genentech, Inc.$8K
  • AstraZeneca$6K
  • Novartis$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Incyte Corporation$2K
  • plus $23K from 54 others

What the payments were for

  • Speaking & faculty fees$2081%
  • Food & beverage$34,79294%
  • Education$1,2923%
  • Other$7322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer102$463,953
Genentech, Inc.2$7,500
AstraZeneca(2 entities)192$5,514
Novartis128$2,705
E.r. Squibb & Sons, L.L.C.127$2,206
Incyte Corporation88$2,203
Johnson & Johnson(2 entities)79$1,744
Bristol Myers Squibb70$1,602
Amgen72$1,523
Pfizer90$1,436
Sanofi60$1,320
Puma Biotechnology, Inc.49$1,290
Daiichi Sankyo Inc.54$1,095
Merck56$1,063
Gilead(2 entities)53$998
Genentech USA, Inc.48$747
Karyopharm Therapeutics Inc.28$656
Pharmacyclics LLC, An Abbvie Company22$598
GSK23$552
Seagen Inc.12$530
Takeda Pharmaceuticals U.S.A., Inc.19$520
Jazz Pharmaceuticals Inc.6$492
Lilly USA, LLC26$463
Foundation Medicine, Inc.13$410
Acrotech Biopharma Inc.11$385
EMD Serono, Inc.15$363
AbbVie15$331
Pharmaessentia USA Corporation13$313
Tersera Therapeutics LLC12$287
Array Biopharma Inc14$269
Taiho Oncology, Inc.11$268
Astellas Pharma US Inc12$257
Eisai Inc.12$229
AVEO Pharmaceuticals, Inc.10$228
Spectrum Pharmaceuticals Inc.12$219
Agios Pharmaceuticals, Inc.9$208
Stemline Therapeutics Inc.6$184
Boehringer Ingelheim10$183
Dendreon Pharmaceuticals LLC7$178
Coherus Oncology, Inc.8$170
Exelixis Inc.10$151
Sobi, Inc5$137
Rigel Pharmaceuticals, Inc.5$134
Regeneron Healthcare Solutions, Inc.5$110
Beigene USA, Inc.4$106
Ipsen Biopharmaceuticals, Inc5$103
Janssen Scientific Affairs, LLC1$102
Novocure Inc.5$101
Mirati Therapeutics, Inc.5$99
Immunocore Limited1$97
Verastem, Inc.3$91
Sumitomo Pharma America, Inc.5$88
Genmab U.S., Inc.3$85
Kyowa Kirin, Inc.4$84
Partner Therapeutics, Inc.5$82
Tesaro, Inc.3$77
Azurity Pharmaceuticals, Inc.4$77
Myovant Sciences Inc.5$75
Immunogen, Inc.4$70
Clovis Oncology, Inc.3$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$508,014 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$1,684,743
Medicare patients
236
Services billed
83,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5046$656,088
ImbruvicaIbrutinib25$385,065
OctagamImmun Globg(Igg)/Malt/Iga Ov5060$322,339
TecentriqAtezolizumab16$169,827
AvastinBevacizumab32$158,553
ThalomidThalidomide11$142,967
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$126,691
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres17$114,627
ProcritEpoetin Alfa29$106,288
Lupron DepotLeuprolide Acetate43$83,629
Evenity (2 Syringes)Romosozumab-Aqqg25$60,013
ProliaDenosumab36$58,001
EliquisApixaban87$56,825
Everolimus12$23,257
Metformin Er GastricMetformin Hcl14$19,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$598$385,06525 claims
PfizerOctagam, Eliquis$1,436$379,164147 claims
Genentech, Inc.Tecentriq, Avastin$7,500$328,38048 claims
Bristol Myers SquibbThalomid$1,602$142,96711 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$520$126,69116 claims
Johnson & JohnsonProcrit, Xarelto$1,744$122,48156 claims
AmgenEvenity (2 Syringes), Prolia$1,523$118,01461 claims
NovartisSandostatin Lar Depot$2,705$114,62717 claims
AbbVieLupron Depot, Synthroid$331$84,06554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in West Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →